At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Talazoparib +1 moredrug
Likely dose
Talazoparib 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Talazoparib and Avelumab for Metastatic Renal Cell Carcinoma and 2 related conditions. Completed, enrolled 18 participants across 7 sites.
Detailed Summary
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedAug 2019
Primary CompletionDec 2023
TodayJul 2026
First PostedAug 28, 2019
Enrollment StartAug 22, 2019
Primary CompletionDec 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.8 years ago
Interventions
Talazoparibdrug
1 mg talazoparib daily
Avelumabdrug
800 mg avelumab every 2 weeks